INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Medical University of Lublin
Lublin, PoloniaPublicaciones en colaboración con investigadores/as de Medical University of Lublin (9)
2021
-
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
International Journal of Cancer, Vol. 149, Núm. 2, pp. 327-336
2020
-
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Blood Cancer Journal, Vol. 10, Núm. 9
2018
-
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
The Lancet Oncology, Vol. 19, Núm. 3, pp. 370-381
2015
-
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2013
-
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 4, pp. 448-455
-
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255
2008
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917